Skip to main content
v2026.11,986 entries · CC-BY 4.0
LAC HealthSponsored

Shop sledai supplies

  • FDA registered
  • ISO 13485
  • BBB Accredited A+

Shop at LAC Health

SLEDAI: Systemic Lupus Erythematosus Disease Activity Index Explained

SLEDAI explained: how the lupus disease activity index was derived, its organ-system weights, max score, and how SLEDAI-2K differs from the original.

Written and maintained by CASRAI Editorial Board

Published

On this page

Research-use information only, not medical advice. This page describes a published measurement instrument. It does not tell anyone how to interpret an individual score or make treatment decisions.

Short answer

SLEDAI, the Systemic Lupus Erythematosus Disease Activity Index, is a weighted clinical index that summarises how active systemic lupus erythematosus (SLE) is across nine organ systems. It was derived in 1992 by the Committee on Prognosis Studies in SLE and later revised as SLEDAI-2K in 2002. Its theoretical maximum is 105.

Definition and scope

The original SLEDAI paper set out to standardise outcome measures in SLE. The authors identified three indices that could describe outcome: disease activity, damage from disease, and health status. SLEDAI is the disease activity index. It is not a damage index and not a health-status questionnaire.

The authors describe it as a validated model of experienced clinicians’ global assessments of disease activity in lupus, representing the consensus of a group of experts in the field of lupus research (Bombardier et al., 1992). It is a tool used by rheumatology researchers and clinicians to record activity in a consistent way, much as other fields use structured scales such as the modified early warning score or CTCAE for their own domains.

How SLEDAI was built and scored

According to the derivation paper’s abstract:

  • Twenty-four clinical variables were identified as important for a disease activity index.
  • These were used to generate 574 patient profiles, each rated on a 0-10 disease activity scale by 14 rheumatologists.
  • A second rating of 10 of the profiles gave scores not significantly different from the first, which the authors took to show that experienced clinicians can reliably make global estimates of disease activity.
  • Multiple regression estimated the relative importance of each variable in the physicians’ ratings. Models were fitted on a training set of 75% of the ratings and validated on the remaining 25%.
  • The regression coefficients for the organ systems were simplified for easier use in clinical practice, producing a weighted index of nine organ systems.

Organ-system weights in the original SLEDAI

Weight Organ systems
8 Central nervous system; vascular
4 Renal; musculoskeletal
2 Serosal; dermal; immunologic
1 Constitutional; hematologic

The maximum theoretical score is 105, but the authors note that in practice few patients score above 45. In the testing set, SLEDAI predicted the physicians’ ratings with Pearson correlation coefficients of 0.64 to 0.79.

SLEDAI vs SLEDAI-2K and later variants

SLEDAI-2K, published by Gladman, Ibanez and Urowitz in 2002, revises the original. The key change is that SLEDAI-2K counts persistent active disease in descriptors where the original counted only new or recurrent activity. Persistent activity is now captured for rash, mucous membranes, alopecia and proteinuria.

Feature SLEDAI (1992) SLEDAI-2K (2002)
Method Physician-rating profiles, regression, simplified weights Revision of the original descriptors
Persistent activity Counted new or recurrent only for some descriptors Also captured for rash, mucous membranes, alopecia, proteinuria
Validation reported 75/25 training and testing split; r = 0.64-0.79 against physician rating 960-patient cohort, plus a 212-patient subgroup seen at five visits 3-6 months apart (1991-93); r = 0.97 with the original
Mortality Both predicted mortality equally (p = 0.0001) in the 2002 comparison

Later published variants

The same research group has since published further work built on SLEDAI-2K. These titles are listed so readers can find the primary literature; consult each paper for what it reports.

  • “SLEDAI-2K for a 30-day window” (Lupus, 2010; PMID 19910390)
  • “SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation” (Lupus, 2011; PMID 21233149)
  • “SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years” (Lupus, 2012; PMID 22800940)
  • “SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement” (Journal of Rheumatology, 2015; PMID 26077403)
  • “A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index” (Rheumatology, 2018; PMID 29688532)

Where it matters for labs and clinics

Because the index was designed to standardise outcome measures, it gives studies and clinics a common language for SLE activity. A study that reports activity needs to say which version it used, since the original and SLEDAI-2K treat persistent activity differently, and the variant titles above show that observation windows also differ (10 days and 30 days appear in published titles). Comparing scores across papers is only meaningful when the version and window match.

Common misunderstandings

  • “The maximum is 105, so scores are spread across 0-105.” 105 is a theoretical maximum; the derivation paper states few patients exceed 45.
  • “SLEDAI measures damage.” It measures disease activity. Damage and health status were separate outcome domains in the same standardisation effort.
  • “SLEDAI and SLEDAI-2K are interchangeable.” They correlate very highly (r = 0.97 in the 2002 validation), but they are different instruments, and SLEDAI-2K counts persistent activity for several descriptors.
  • “A score is a diagnosis or treatment instruction.” It is a research and clinical summary of activity; interpretation belongs with a treating clinician.

FAQ

What does SLEDAI stand for?

Systemic Lupus Erythematosus Disease Activity Index.

Who developed SLEDAI?

Bombardier, Gladman, Urowitz, Caron and Chang, for the Committee on Prognosis Studies in SLE, published in Arthritis and Rheumatism in 1992.

What is the highest possible SLEDAI score?

105 in theory; in practice few patients score above 45, according to the original paper.

What is SLEDAI-2K?

A 2002 revision that also counts persistent activity for rash, mucous membranes, alopecia and proteinuria.

Sources

  1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH; Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630-640. PubMed 1599520 (read 2026-11-07).
  2. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002. PubMed 11838846 (read 2026-11-07).
  3. Variant papers listed above, identified by PubMed ID (titles checked 2026-11-07).

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about SLEDAI: Systemic Lupus Erythematosus Disease Activity Index Explained

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →